Please Wait.....
Report
Deferiprone Market? By Form (Tablets, Others) , By Application (Transfusional Iron Overload, NTDT Caused Overload.) By Distribution Channel (Hospital Pharmacies, Drug store & retail pharmacies, Online providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Market Report I 2024-07-01 I 280 Pages I Allied Market Research
Deferiprone Market
The deferiprone marketwas valued at $33.4 million in 2023 and is projected to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.
Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.
The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of metastatic ovarian cancer.
However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual's health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum to no possibility of causing side effects to the human body.
Segment Review
The deferiprone market is segmented into form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of form, the tablets segment dominated the market in 2023.
As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.
Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.
Region wise, North America was the highest revenue generator in the market in 2023.
Competition Analysis
The key players operating in theglobal deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Taro Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A, Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Form
- Tablets
- Others
By Application
- Transfusional Iron Overload
- NTDT Caused Overload.
By Distribution Channel
- Hospital Pharmacies
- Drug store retail pharmacies
- Online providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Apotex Inc
- Cipla Limited
- VHB Life Sciences Limited
- Taro Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Novartis International AG
- Chiesi Farmaceutici S.p.A
- Zydus Cadila
- Cipla Inc.
- Pfizer
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: UROKINASE MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Urokinase Powder
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Urokinase Solution
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: UROKINASE MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospital
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: UROKINASE MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Urokinase Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Urokinase Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Urokinase Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Urokinase Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Urokinase Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Urokinase Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Urokinase Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Urokinase Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Urokinase Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Urokinase Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Urokinase Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Urokinase Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Urokinase Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Urokinase Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Urokinase Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Urokinase Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Urokinase Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Urokinase Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Urokinase Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. NDpharm
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Wanhua Biochem
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Jiangxi Haoran Bio-Pharma
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Jiangsu Aidea Pharmaceutical
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Techpool
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Microbic Biosystems Inc
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Livzon Pharmaceutical Group Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Cadila Healthcare Limited
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. TAJ Pharmaceuticals Limited
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Microbix Biosystems Inc
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
TABLE 1. GLOBAL DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 2. DEFERIPRONE MARKET FOR TABLETS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 3. DEFERIPRONE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 4. GLOBAL DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 5. DEFERIPRONE MARKET FOR TRANSFUSIONAL IRON OVERLOAD, BY REGION, 2024 - 2033 ($MILLION)
TABLE 6. DEFERIPRONE MARKET FOR NTDT CAUSED OVERLOAD., BY REGION, 2024 - 2033 ($MILLION)
TABLE 7. GLOBAL DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 8. DEFERIPRONE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 9. DEFERIPRONE MARKET FOR DRUG STORE RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($MILLION)
TABLE 10. DEFERIPRONE MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($MILLION)
TABLE 11. DEFERIPRONE MARKET, BY REGION, 2024 - 2033 ($MILLION)
TABLE 12. NORTH AMERICA DEFERIPRONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 13. NORTH AMERICA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 14. NORTH AMERICA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 15. NORTH AMERICA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 16. U.S. DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 17. U.S. DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 18. U.S. DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 19. CANADA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 20. CANADA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 21. CANADA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 22. MEXICO DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 23. MEXICO DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 24. MEXICO DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 25. EUROPE DEFERIPRONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 26. EUROPE DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 27. EUROPE DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 28. EUROPE DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 29. FRANCE DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 30. FRANCE DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 31. FRANCE DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 32. GERMANY DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 33. GERMANY DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 34. GERMANY DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 35. ITALY DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 36. ITALY DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 37. ITALY DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 38. SPAIN DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 39. SPAIN DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 40. SPAIN DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 41. UK DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 42. UK DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 43. UK DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 44. REST OF EUROPE DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 45. REST OF EUROPE DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 46. REST OF EUROPE DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 47. ASIA-PACIFIC DEFERIPRONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 48. ASIA-PACIFIC DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 49. ASIA-PACIFIC DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 50. ASIA-PACIFIC DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 51. CHINA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 52. CHINA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 53. CHINA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 54. JAPAN DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 55. JAPAN DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 56. JAPAN DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 57. INDIA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 58. INDIA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 59. INDIA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 60. SOUTH KOREA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 61. SOUTH KOREA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 62. SOUTH KOREA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 63. AUSTRALIA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 64. AUSTRALIA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 65. AUSTRALIA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 69. LAMEA DEFERIPRONE MARKET, BY COUNTRY, 2024 - 2033 ($MILLION)
TABLE 70. LAMEA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 71. LAMEA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 72. LAMEA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 73. BRAZIL DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 74. BRAZIL DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 75. BRAZIL DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 76. SOUTH AFRICA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 77. SOUTH AFRICA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 78. SOUTH AFRICA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 79. SAUDI ARABIA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 80. SAUDI ARABIA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 81. SAUDI ARABIA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 82. REST OF LAMEA DEFERIPRONE MARKET, BY FORM, 2024 - 2033 ($MILLION)
TABLE 83. REST OF LAMEA DEFERIPRONE MARKET, BY APPLICATION, 2024 - 2033 ($MILLION)
TABLE 84. REST OF LAMEA DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($MILLION)
TABLE 85. APOTEX INC: KEY EXECUTIVES
TABLE 86. APOTEX INC: COMPANY SNAPSHOT
TABLE 87. APOTEX INC: OPERATING SEGMENTS
TABLE 88. APOTEX INC: PRODUCT PORTFOLIO
TABLE 89. APOTEX INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90. CIPLA LIMITED: KEY EXECUTIVES
TABLE 91. CIPLA LIMITED: COMPANY SNAPSHOT
TABLE 92. CIPLA LIMITED: OPERATING SEGMENTS
TABLE 93. CIPLA LIMITED: PRODUCT PORTFOLIO
TABLE 94. CIPLA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 95. VHB LIFE SCIENCES LIMITED: KEY EXECUTIVES
TABLE 96. VHB LIFE SCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 97. VHB LIFE SCIENCES LIMITED: OPERATING SEGMENTS
TABLE 98. VHB LIFE SCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 99. VHB LIFE SCIENCES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 101. TARO PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 102. TARO PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 103. TARO PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 104. TARO PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 106. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 107. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 108. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 109. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 110. NOVARTIS INTERNATIONAL AG: KEY EXECUTIVES
TABLE 111. NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
TABLE 112. NOVARTIS INTERNATIONAL AG: OPERATING SEGMENTS
TABLE 113. NOVARTIS INTERNATIONAL AG: PRODUCT PORTFOLIO
TABLE 114. NOVARTIS INTERNATIONAL AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. CHIESI FARMACEUTICI S.P.A: KEY EXECUTIVES
TABLE 116. CHIESI FARMACEUTICI S.P.A: COMPANY SNAPSHOT
TABLE 117. CHIESI FARMACEUTICI S.P.A: OPERATING SEGMENTS
TABLE 118. CHIESI FARMACEUTICI S.P.A: PRODUCT PORTFOLIO
TABLE 119. CHIESI FARMACEUTICI S.P.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 120. ZYDUS CADILA: KEY EXECUTIVES
TABLE 121. ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 122. ZYDUS CADILA: OPERATING SEGMENTS
TABLE 123. ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 124. ZYDUS CADILA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125. CIPLA INC.: KEY EXECUTIVES
TABLE 126. CIPLA INC.: COMPANY SNAPSHOT
TABLE 127. CIPLA INC.: OPERATING SEGMENTS
TABLE 128. CIPLA INC.: PRODUCT PORTFOLIO
TABLE 129. CIPLA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 130. PFIZER: KEY EXECUTIVES
TABLE 131. PFIZER: COMPANY SNAPSHOT
TABLE 132. PFIZER: OPERATING SEGMENTS
TABLE 133. PFIZER: PRODUCT PORTFOLIO
TABLE 134. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
FIGURE 1. GLOBAL DEFERIPRONE MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF DEFERIPRONE MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN DEFERIPRONE MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDEFERIPRONE MARKET
FIGURE 10. GLOBAL DEFERIPRONE MARKET SEGMENTATION, BY FORM
FIGURE 11. DEFERIPRONE MARKET FOR TABLETS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 12. DEFERIPRONE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 13. GLOBAL DEFERIPRONE MARKET SEGMENTATION, BY APPLICATION
FIGURE 14. DEFERIPRONE MARKET FOR TRANSFUSIONAL IRON OVERLOAD, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 15. DEFERIPRONE MARKET FOR NTDT CAUSED OVERLOAD., BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 16. GLOBAL DEFERIPRONE MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
FIGURE 17. DEFERIPRONE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 18. DEFERIPRONE MARKET FOR DRUG STORE RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 19. DEFERIPRONE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($MILLION)
FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 24. COMPETITIVE DASHBOARD
FIGURE 25. COMPETITIVE HEATMAP: DEFERIPRONE MARKET
FIGURE 26. TOP PLAYER POSITIONING, 2023
FIGURE 27. APOTEX INC: NET SALES, 2021-2023 ($MILLION)
FIGURE 28. APOTEX INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. APOTEX INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. CIPLA LIMITED: NET SALES, 2021-2023 ($MILLION)
FIGURE 31. CIPLA LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. CIPLA LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. VHB LIFE SCIENCES LIMITED: NET SALES, 2021-2023 ($MILLION)
FIGURE 34. VHB LIFE SCIENCES LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. VHB LIFE SCIENCES LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. TARO PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($MILLION)
FIGURE 37. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. TARO PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($MILLION)
FIGURE 40. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. NOVARTIS INTERNATIONAL AG: NET SALES, 2021-2023 ($MILLION)
FIGURE 43. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. NOVARTIS INTERNATIONAL AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. CHIESI FARMACEUTICI S.P.A: NET SALES, 2021-2023 ($MILLION)
FIGURE 46. CHIESI FARMACEUTICI S.P.A: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. CHIESI FARMACEUTICI S.P.A: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. ZYDUS CADILA: NET SALES, 2021-2023 ($MILLION)
FIGURE 49. ZYDUS CADILA: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. ZYDUS CADILA: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. CIPLA INC.: NET SALES, 2021-2023 ($MILLION)
FIGURE 52. CIPLA INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. CIPLA INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. PFIZER: NET SALES, 2021-2023 ($MILLION)
FIGURE 55. PFIZER: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. PFIZER: REVENUE SHARE, BY REGION, 2023 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security